Current treatment options in follicular lymphoma: Science and bias

References

• Young R C, Longo D L, Glatstein E, Ihde D C, Jaffe E S, De Vita V T, Jr. Treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; 25(Suppl 2)11–16
   PubMed Web of Science ®Google Scholar
• Cheson B D. Anti-CD20 Monoclonal Antibodies in the Treatment of Indolent Lymphoma and CLL. Clin Adv Hematol Oncol 2007; 5(Suppl 3)1–16
   PubMedGoogle Scholar
• Schulz H, Bohlius J F, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706–714
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of Interleukin-10 by rituximab Results in Down-regulation of Bcl-2 and Sensitization of B-cell Non-Hodgkin's Lymphoma to Apopotosis. Clinical Cancer Research 2001; 7: 709–723
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Pro B, Lopez-Guillermo A, Marcheselli L, Trneny M, et al. Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy. J Clin Oncol (Proc ASCO) 2007, abstr. 8008
   Google Scholar
• Longo D L. What's the deal with follicular lymphomas?. J Clin Oncol 1993; 11: 202–208
   PubMed Web of Science ®Google Scholar
• Anderson J R, Vose J M, Bierman P J, Weisenberger D D, Sanger W G, Pierson J, et al. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol 1993; 11: 218–224
   PubMed Web of Science ®Google Scholar
• Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez M A, et al. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973 – 1981. Ann Oncol 2000; 11: 1551–1556
   PubMed Web of Science ®Google Scholar
• Rodriguez J, McLaughlin P, Hagemeister F B, Fayad L, Rodriguez M A, Santiago M, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93: 2202–2207
   PubMed Web of Science ®Google Scholar
• Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D, et al. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1654–1663
   PubMed Web of Science ®Google Scholar
• Advani R, Rosenberg S A, Horning S J. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454–1459
   PubMed Web of Science ®Google Scholar
• Tezcan H, Vose J M, Bast M, Bierman P J, Kessinger A, Armitage J. Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience. Leuk Lymphoma 1999; 34: 273–285
   PubMed Web of Science ®Google Scholar
• Seymour J F, Pro B, Fuller L M, Manning J T, Hagemeister F B, Romaguera J, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 2115–2122
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Jazirehi A, Bonavida B. Rituximab-mediated sensitization of B-Non-Hodgkin Lymphoma to cytotoxicity induced by Paclitaxel, Gemcitabine and Vinorelbine. Cancer Biotherapy & Radiopharmaceuticals 2002; 17: 621–630
   PubMed Web of Science ®Google Scholar
• Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's Lymphoma by pentoxifyllilne and rituximab. Anticancer Research 2000; 20: 2961–2966
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-López A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-López A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-Year follow-up. J Clin Oncol 2004; 22: 4711–4716, Erratum: J Clin Oncol 2005;23:248
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694–704
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Rosen P, Telatar M, Malone R, Bosserman L, Menco H, et al. Excellent tolerance of Rituxan when administered after cyclophosphamide - mitoxantrone. An effective regimen in NHL. Clin Lymphoma 2000; 1: 146–151, discussion 152 – 153
   PubMedGoogle Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Fisher R I, LeBlanc M, Press O W, Maloney D G, Unger J M, Miller T P. New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma. J Clin Oncol 2005; 23: 8447–8452
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Marcus R E, Solal-Celigny P, Imrie K, Catalano J V, Dmoszynska A, Raposo J C, et al. Mabthera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin's Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2006; 108: 481
   Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986–1992
   PubMed Web of Science ®Google Scholar
• Foussard C, Mounier N, Van Hoof A, Delwail V, Casasnovas O, Deconinck E, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol (Proc ASCO) 2006; 24(Suppl), abstr. 7508
   Google Scholar
• Roswitha F, Unterhalt M, Dreyling M, Böck H P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• Bagley C M, Jr, Devita V T, Jr, Berard C W, Canellos G P. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine and prednisolone. Ann Intern Med 1972; 76: 227–232
   PubMed Web of Science ®Google Scholar
• Kimby E, Bjorkholm M, Gahrton G, Glimelius B, Hagberg H, Johannson B, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; 5(Suppl 2)67–71
   PubMedGoogle Scholar
• Dana B W, Dahlberg S, Nathwani B N, Chase E, Coltman C, Miller T P, et al. Long-term follow-up of patients with low grade malignant lymphomas treated with doxorubicin-based therapy or chemoimmunotherapy. J Clin Oncol 1993; 11: 644–651
   PubMed Web of Science ®Google Scholar
• Hochster H, Cassileth P. Fludarabine phosphate therapy in non-Hodgkin's lymphoma. Semin Oncol 1990; 17(Suppl 8)63–65
   PubMed Web of Science ®Google Scholar
• Pigaditou A, Rohatiner A Z, Whelan J S, Johnson P W, Ganjoo R K, Rossi A, et al. Fludarabine in low-grade lymphoma. Semin Oncol 1993; 20(Suppl 7)24–27
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Hagemeister F B, Romaguera J E, Sarris A H, Pate O, Younes A, et al. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262–1268
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Rosen P, Rasti S, Territo M, Kunkel L. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial. Hematol Oncol 1998; 16: 107–116
   PubMed Web of Science ®Google Scholar
• Seymour J F, Grigg A P, Szer J, Fox R M. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol 2001; 12: 1455–1460
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Lew D, Grogan T M, Spiridonidis C H, Balcerzak S P, Dakhil S R, et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 2003; 21: 1996–2003
   PubMed Web of Science ®Google Scholar
• Hochster H S, Oken M M, Winter J N, Gordon L I, Raphael B G, Bennett J M, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up – a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000; 18: 987–994
   PubMed Web of Science ®Google Scholar
• Flinn I W, Byrd J C, Morrison C, Jamison J, Diehl L F, Murphy T, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71–75
   PubMed Web of Science ®Google Scholar
• Hochster H S, Weller E, Gascoyne R D, Ryan T, Habermann T M, Gordon L I, et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial. J Clin Oncol (Proc ASCO) 2007; 25(Suppl), abstr. 8004
   Google Scholar
• Santini G, Chisesi T, Nati S, Porcellini A, Zoli V, Rizzoli V, et al. Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group. Leuk Lymphoma 2004; 45: 1141–1147
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin P J, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 1590–1596
   PubMed Web of Science ®Google Scholar
• Klasa R J, Mayer R M, Shustik C, Sawka C A, Smith A, Guevin R, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 2002; 20: 4649–4654
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as frond-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654–2661
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329: 1608–1614
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S F, Cogliatti S B, Pichert S B, Hummerjohan J, Walzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood 2004; 103: 4416–4423
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Shaffer D W, Lackey V L, Grimaldi M, Greco F A, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1095
   PubMed Web of Science ®Google Scholar
• Emmanouilides C. Radioimmunotherapy in non-Hodgkin Lymphoma. Semin Oncol 2003; 30: 531–544
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Witzig T E, Gordon L I, Vo K, Wiseman G A, Flinn I W, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 629–636
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Estes J, Tuck M, Ross W, Wahl R L. I131-tositumomab monotherapy as frontline treatment for follicular lymphoma: Updated results after a median follow-up of 8 years. J Clin Oncol (Proc ASCO) 2007; 25(Suppl), abstr. 8033
   Google Scholar
• Sweetenham J W, Karel Dicke K, John Arcaroli J, et al. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Therapy with Rituximab Maintenance in Patients with Untreated Low-Grade Follicular Lymphoma. Blood (ASH Annu Meet) 2004; 104: abstr. 2633
   Google Scholar
• Press O W, Unger J M, Braziel R M, Malone D G, Miller T P, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006; 24: 4143–4149
   PubMed Web of Science ®Google Scholar
• Jankowitz R C, Foon K A, DeMonaco N A, Osborn J, Wu M, Evans T, et al. Phase II study of short course CHOP-rituximab followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL). J Clin Oncol (Proc ASCO) 2007; 25(Suppl), abstr. 8005
   Google Scholar
• Shipley D L, Spigel D R, Carrell D L, Dannaher F A, Greco J D, Hainsworth J D. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network. J Clin Oncol (Proc ASCO Post Meet Ed) 2004; 22(Suppl), abstr. 6519
   Google Scholar
• Zinzani P L, Pulsoni A, Balocco M, Tani M, Fanti S, Perroti A, et al. A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients. Blood (ASH Annu Meet Abstr) 2006; 108: abstr. 2479
   Google Scholar
• Hainsworth J D, Litchy S, Shaffer D W, Lackey V L, Grimaldi M, Greco F A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1095
   PubMed Web of Science ®Google Scholar
• Hiddemann W. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol 2003; 14: 1163–1164
   PubMed Web of Science ®Google Scholar
• Dreyling M, Forstpointner R, Gramatzki M, Boeck H, Haenel M, Seymour J, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol (Proc ASCO) 2006;24(Suppl): abstr. 7502
   Google Scholar
• Van Oers M HJ, Van Glabbeke M, Teodorovic I, Rozewicz C, Klaza C RR, Marcus R, et al. Chimeric Anti-CD20 Monoclonal Antibody (Rituximab; Mabtheraa) in Remission Induction and Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: A Phase III Randomized Intergroup Clinical Trial. Blood (ASH Annu Meet Abstr) 2004; 104: abstr. 586
   Google Scholar
• Howard S. Hochster, Weller E, Gascoyne R D, Ryan T S, Habermann T M, et al. Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (ASH Annu Meet Abstr) 2005; 106: abstr. 349
   Google Scholar
• Hanbali A, Khaled Y, Ajrouche H, Ansari A, Janakiraman N. Incidence of Hepatitis B Reactivation in Association with Rituximab Therapy. Blood (ASH Annu Meet Abstr) 2006; 108: abstr. 2766
   Google Scholar
• Li Y H, He Y F, Jiang W Q, Wang F H, Lin X B, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320–1325
   PubMed Web of Science ®Google Scholar
• Emmanouilides C. Low grade lymphoma: Chapter. Current Clinical Oncology: Chronic Leukemias and Lymphomas, G J Schiller. Humana Press Inc, NJ 2005; 249–275
   Google Scholar
• Williams M E, Cohen P, Tulpule A, Van der Jagt R H, Herst J A, Bessudo A, et al. A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol (Proc ASCO) 2006;24(Suppl): abstr. 7528
   Google Scholar
• Horning S J. High-dose therapy and transplantation for low-grade lymphoma. Hematol Oncol Clin North Am 1997; 11: 919–935
   PubMed Web of Science ®Google Scholar
• Cao T M, Horning S, Negrin R S, Hu W W, Johnston L J, Taylor T L, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7: 294–301
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Lill M, Telatar M, Menco H, Patel R, Territo M, et al. MINE-rituxan salvage and in vivo purging for patients with NHL undergoing transplant. Clinical Lymphoma 2002; 3: 111–116
   PubMedGoogle Scholar
• Rohatiner A ZS, Nadler L, Davies A J, Apostolidis J, Neuberg D, Matthews J, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J clin Oncol 2007; 25: 2554–2559
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540–2544
   PubMed Web of Science ®Google Scholar
• Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFevre P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105: 3817–3823
   PubMed Web of Science ®Google Scholar
• de Vos S, Dakhil S, McLaughlin P, Saleh M, Belt R, Flowers C, et al. Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin's Lymphoma (NHL): A Phase 2 Study. Blood (ASH Annu Meet Abstr) 2005; 106: 17
   Google Scholar
• Leonard J P, Coleman M, Ketas J C, Chadburn A, Ely S, Furman R R, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3051–3059
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Leonard J P, Schuster S J, Couture F, Mills A, Koutsoukos A, et al. Multi-Center, phase 2 study of combination antibody therapy with Epratuzumab plus Rituximab in recurring low-grade NHL. Blood 2003; 102: 69a
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Thall A, Witzig T E, Vose J M, Younes A, Emmanouilides C, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23: 4390–4398
   PubMed Web of Science ®Google Scholar
• Fanale M A, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67: 333–350
   PubMed Web of Science ®Google Scholar
• Maloney D G. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005; 23: 6421–6428
   PubMed Web of Science ®Google Scholar